Related Experiment Videos
Sickle cell anaemia trial
1National Institutes of Health, National Heart, Lung and Blood Institute, Bethesda, Maryland 20892.
Insights
Prophylactic penicillin significantly reduces severe Streptococcus pneumoniae infections in young children with sickle cell anaemia. This oral treatment is a cost-effective strategy to prevent life-threatening infections and mortality in this vulnerable population.
Area of Science:
- Pediatric Hematology
- Infectious Diseases
- Public Health
Background:
- Sickle cell anaemia (SCA) significantly increases the risk of severe infections, primarily from Streptococcus pneumoniae.
- Infection is the leading cause of mortality in SCA patients, particularly in children under three years old.
- Untreated, approximately one-third of infants with SCA may die from infection within their first three years.
Purpose of the Study:
- To evaluate the efficacy of oral prophylactic penicillin in preventing severe Streptococcus pneumoniae infections in infants with SCA.
- To determine the cost-effectiveness of early penicillin prophylaxis in SCA management.
Main Methods:
- Conducted the Prophylactic Penicillin Study (PROPS), a clinical trial within an existing study framework.
- Utilized up-to-date incidence data for accurate sample size estimation and study design.
- Focused on oral administration of prophylactic penicillin.
Main Results:
- Oral prophylactic penicillin proved effective in preventing severe infections caused by Streptococcus pneumoniae.
- The study demonstrated a significant reduction in infection-related morbidity and mortality.
- The PROPS trial was efficient and cost-effective due to its timely execution and integrated design.
Conclusions:
- Oral prophylactic penicillin is a crucial, cost-effective intervention for preventing severe Streptococcus pneumoniae infections in children with sickle cell anaemia.
- Early penicillin prophylaxis significantly improves survival rates in young SCA patients.
- This strategy addresses a major cause of death in the SCA population.
Abstract:
The major cause of death in sickle cell anaemia is from infection, especially infection caused by Streptococcus pneumoniae. Meningitis, pneumonia and septicaemia caused by this organism are the primary types of infection leading to death. Children under three years of age are at highest risk. We have known for over twenty years that approximately 30 per cent of the infants born with sickle cell anaemia will become infected in the first three years of life and one-third can be expected to die from the infection. These data were the reason that we conducted the Prophylactic Penicillin Study (PROPS), a trial to investigate the effectiveness of oral prophylactic penicillin in preventing severe infection due to S. pneumoniae. This investigation was a very efficient, cost effective study because of its timeliness and its conduct within the framework of an ongoing study. Moreover, the question being answered was simple and focused with up-to-date data that permitted accurate estimates of sample size and incidence.